Correction: Outcomes and Surgical Interventions for Patients with Intestinal Metastases from Advanced Epithelial Ovarian Cancer
By
Hongxia Wang
Yijie Li
Zhifen Yang
Jinxiu Wang
Kaiyun Qin
Yu Yu
Na Wang
Jingde Jia
Wenhong Zhao
Fenghua Zhang
Mario M. Leitao
Ran Meng
Yueping Liu
Yan Ding
Zhengmao Zhang
August 13, 2026
Clinical Scorecard: Correction: Outcomes and Surgical Interventions for Patients with Intestinal Metastases from Advanced Epithelial Ovarian Cancer
At a Glance
Category Detail
Condition Advanced Epithelial Ovarian Cancer with Intestinal Metastases Key Mechanisms Neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) are key components of treatment. Target Population Patients with advanced epithelial ovarian cancer unable to undergo immediate surgery due to extensive disease. Care Setting Oncology surgical and chemotherapy settings
Key Highlights
Correction of inaccuracies in FIGO Stages for ovarian cancer. NACT regimen includes platinum-based chemotherapy (paclitaxel plus carboplatin). Interval debulking surgery (IDS) is performed after NACT. Postoperative chemotherapy is administered based on surgical approach. Follow-up duration for patients ranges from two to ninety-eight months. Guideline-Based Recommendations
Diagnosis
Accurate staging of ovarian cancer is critical for treatment planning. Management
NACT is recommended for patients with high perioperative risk. Monitoring & Follow-up
Regular follow-up is essential to assess treatment response and manage complications. Risks
High perioperative risk may necessitate NACT prior to surgery. Patient & Prescribing Data
Patients with advanced epithelial ovarian cancer and intestinal metastases.
Chemotherapy regimens typically involve platinum-based combinations administered pre- and post-surgery.
Clinical Best Practices
Initiate a liquid diet and oral laxatives for bowel preparation prior to surgery. Ensure accurate staging and treatment planning based on FIGO classification. Related Resources & Content
